Wells Fargo & Company Initiates Coverage on enGene (NASDAQ:ENGN)

Wells Fargo & Company assumed coverage on shares of enGene (NASDAQ:ENGNGet Free Report) in a report released on Monday, Briefing.com reports. The brokerage set an “overweight” rating and a $30.00 price target on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 102.02% from the stock’s current price.

Several other research analysts have also issued reports on the company. SVB Leerink started coverage on enGene in a research report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 target price for the company. Leerink Partnrs restated an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Guggenheim initiated coverage on shares of enGene in a research note on Monday, April 15th. They set a “buy” rating and a $34.00 price target for the company. Morgan Stanley started coverage on enGene in a report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target for the company. Finally, UBS Group started coverage on shares of enGene in a research report on Thursday, March 28th. They set a “buy” rating and a $37.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $34.40.

View Our Latest Report on ENGN

enGene Trading Up 4.8 %

Shares of NASDAQ:ENGN opened at $14.85 on Monday. enGene has a 1 year low of $6.69 and a 1 year high of $43.00. The company has a 50 day moving average price of $15.97.

Hedge Funds Weigh In On enGene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vivo Capital LLC bought a new position in shares of enGene in the fourth quarter worth approximately $6,264,000. Goldman Sachs Group Inc. purchased a new stake in shares of enGene during the 4th quarter valued at $346,000. Royal Bank of Canada bought a new stake in shares of enGene during the 4th quarter worth $349,000. Citadel Advisors LLC purchased a new position in enGene in the fourth quarter worth $185,000. Finally, BVF Inc. IL bought a new position in enGene in the fourth quarter valued at $20,777,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

About enGene

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

Read More

Analyst Recommendations for enGene (NASDAQ:ENGN)

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.